Synergistic enhancement of in vitro nab-paclitaxel responses by PD-L1 immune checkpoint targeted photoactivable liposomes with altered cell-cycle progression and amplified immunogenic signaling
RSC Pharmaceutics · 2027
DOI: 10.1039/d6pm00480f ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2027. Verfasst von Chanda Bhandari und 9 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Institutes of Health, Cancer Prevention and Research Institute of Texas, University of Texas at Dallas.
Abstract (Originalsprache)
iTPALs enhances the therapeutic and immunogenic responses to nab-PTX and establish a rationale for future in vivo evaluation of this combination.
Förderung
- National Institutes of Health
- Cancer Prevention and Research Institute of Texas
- University of Texas at Dallas
Zitieren
APA
Bhandari, C., Malkoochi, A., Walid, D. M., Karambelkar, K., Koya, N., Upreti, A., Mutar, S. A., Brown, T. J., Brekken, R. A., & Obaid, G. (2027). Synergistic enhancement of in vitro nab-paclitaxel responses by PD-L1 immune checkpoint targeted photoactivable liposomes with altered cell-cycle progression and amplified immunogenic signaling. RSC Pharmaceutics. https://doi.org/10.1039/d6pm00480f
Vancouver
Bhandari C, Malkoochi A, Walid DM, Karambelkar K, Koya N, Upreti A, et al. Synergistic enhancement of in vitro nab-paclitaxel responses by PD-L1 immune checkpoint targeted photoactivable liposomes with altered cell-cycle progression and amplified immunogenic signaling. RSC Pharmaceutics. 2027. doi:10.1039/d6pm00480f
BibTeX
@article{Bhandari2027,
author = {Bhandari, Chanda and Malkoochi, Ashritha and Walid, Doha Mahmoud and Karambelkar, Kunal and Koya, Nikhita and Upreti, Aarati and Mutar, Salwan Al and Brown, Timothy J. and Brekken, Rolf A. and Obaid, Girgis},
title = {Synergistic enhancement of in vitro nab-paclitaxel responses by PD-L1 immune checkpoint targeted photoactivable liposomes with altered cell-cycle progression and amplified immunogenic signaling},
journal = {RSC Pharmaceutics},
year = {2027},
doi = {10.1039/d6pm00480f}
}
EUVIMED